Form 4 Tharimmune, Inc. For: Aug 09 Filed by: Anderson Kelly
Tharimmune, Inc. (THAR)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
THAR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
THAR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
THAR alerts
High impacting Tharimmune, Inc. news events
Weekly update
A roundup of the hottest topics
THAR
News
- Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of InfliximabAccesswire
- Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory BoardAccesswire
- Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor [Yahoo! Finance]Yahoo! Finance
- Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic AdvisorAccesswire
- Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104Accesswire
THAR
Sec Filings
- 9/16/24 - Form 8-K
- 8/12/24 - Form 4
- 8/12/24 - Form 4
- THAR's page on the SEC website